MilliporeSigma to Supply Lotte Biologics with Biologics Manufacturing Capabilities in US

Published on: 

MilliporeSigma and Lotte Group will collaborate on facility design and workforce training for a new biologics business unit in the US.

On June 29, 2022, MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced it has signed a non-binding memorandum of understanding (MoU) with the Lotte Group.

Under the MoU, MilliporeSigma will collaborate with the new biologics business of Lotte to establish Lotte’s biologics manufacturing capabilities in the United States. MilliporeSigma will be a preferred supplier who will provide Lotte with technical consulting, training and expertise, products, technologies, and manufacturing solutions.

“Novel modalities are changing the landscape of medicine and are expected to rapidly expand in the coming years to support development of customized, next-generation therapies, drugs, and vaccines,” said Andrew Bulpin, head of process solutions, Life Science, Merck KGaA, Darmstadt, Germany, in a company press release.


“We are delighted to announce our collaboration with MilliporeSigma. We believe such a relationship is a perfect fit for our mutual growth and business value and we look forward to strengthening and fostering this partnership not only in the US, but further on a global level to place both parties on the best path for consistent success,” said Richard Lee, CEO, Lotte Biologics, in the release.

Source: MilliporeSigma